| Literature DB >> 28432574 |
Carmelo Messina1, Bianca Bignotti2, Alberto Bazzocchi3, Catherine M Phan4, Alberto Tagliafico5, Giuseppe Guglielmi6, Francesco Sardanelli7,8, Luca Maria Sconfienza9,10.
Abstract
OBJECTIVES: Dual energy X-ray absorptiometry (DXA) is the most widely used technique to measure bone mineral density (BMD). Appropriate and accurate use of DXA is of great importance, and several guidelines have been developed in the last years. Our aim was to evaluate the quality of published guidelines on DXA for adults.Entities:
Keywords: Agree; DXA; Dual-energy X-ray absorptiometry; Evidence based medicine; Guidelines
Year: 2017 PMID: 28432574 PMCID: PMC5438319 DOI: 10.1007/s13244-017-0553-6
Source DB: PubMed Journal: Insights Imaging ISSN: 1869-4101
Summary of AGREE II structure and detailed list of items within each domain (from reference 15)
| Domain 1. Scope and Purpose | |
| Item 1 | The overall objective(s) of the guideline is (are) specifically described |
| Item 2 | The health question(s) covered by the guideline is (are) specifically described |
| Item 3 | The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described |
| Domain 2: Stakeholder Involvement | |
| Item 4 | The guideline development group includes individuals from all the relevant professional groups |
| Item 5 | The views and preferences of the target population (patients, public, etc.) have been sought |
| Item 6 | The target users of the guideline are clearly defined |
| Domain 3: Rigor of Development | |
| Item 7 | Systematic methods were used to search for evidence |
| Item 8 | The criteria for selecting the evidence are clearly described |
| Item 9 | The strengths and limitations of the body of evidence are clearly described |
| Item 10 | The methods for formulating the recommendations are clearly described |
| Item 11 | The health benefits, side effects and risks have been considered in formulating the recommendations |
| Item 12 | There is an explicit link between the recommendations and the supporting evidence |
| Item 13 | The guideline has been externally reviewed by experts prior to its publication |
| Item 14 | A procedure for updating the guideline is provided |
| Domain 4: Clarity of Presentation | |
| Item 15 | The recommendations are specific and unambiguous |
| Item 16 | The different options for management of the condition or health issue are clearly presented |
| Item 17 | Key recommendations are easily identifiable |
| Domain 5: Applicability | |
| Item 18 | The guideline describes facilitators and barriers to its application |
| Item 19 | The guideline provides advice and/or tools on how the recommendations can be put into practice |
| Item 20 | The potential resource implications of applying the recommendations have been considered |
| Item 21 | The guideline presents monitoring and/or auditing criteria |
| Domain 6: Editorial Independence | |
| Item 22 | The views of the funding body have not influenced the content of the guideline |
| Item 23 | Competing interests of guideline development group members have been recorded and addressed |
General characteristics of DXA guidelines included in the analysis
| DXA guideline title | Country of origin | Year of publication | Organisation |
|---|---|---|---|
| Recommendations for Bone Mineral Density Reporting in Canada [ | Canada | 2005 | Canadian Association of Radiologists |
| International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions [ | USA | 2008 | International Society for Clinical Densitometry |
| ACR Appropriateness Criteria: Osteoporosis and Bone Mineral Density [ | USA | 2010 | American College of Radiology (ACR) |
| ACR-SPR-SSR Practice Parameter for the Performance of Dual-Energy X-Ray Absorptiometry [ | USA | 2014 | American College of Radiology (ACR), Society for Pediatric Radiology (SPR), Society of Skeletal Radiology (SSR) |
Summary of the average of domain scores of DXA Guidelines according to AGREE II
| Guideline title | Domain 1 | Domain 2 | Domain 3 | Domain 4 | Domain 5 | Domain 6 | Total score mean (SD) | Overall quality |
|---|---|---|---|---|---|---|---|---|
| Recommendations for BMD Reporting in Canada [ | 84.7%* (good) | 73.6%* (acceptable) | 57.3% (low) | 77.8%* (acceptable) | 66.7%* (acceptable) | 75.0%* (acceptable) | 72.5% (9.5%) | High |
| ISCD 2007 Adult and Pediatric Official Positions [ | 91.7%* (good) | 76.4%* (acceptable) | 78.6%* (acceptable) | 90.3%* (good) | 78.1%* (acceptable) | 41.7% (low) | 76.1% (18,1%) | High |
| ACR Appropriateness Criteria: Osteoporosis and BMD [ | 88.9%* (good) | 68.1%* (acceptable) | 60.9%* (acceptable) | 87.5%* (good) | 76.0%* (acceptable) | 54.2% (low) | 72.6% (14.1%) | High |
| ACR-SPR-SSR Practice Parameter for the Performance of DXA [ | 81.9%* (good) | 68.1%* (acceptable) | 58.9% (low) | 66.7%* (acceptable) | 61.5%* (acceptable) | 47.9% (low) | 64.1% (11.3%) | Average |
| Total domain score; mean (SD) | 86,8% (3,7%) (good) | 71,5% (3.6%) (acceptable) | 63.9% (8.6%) (acceptable) | 80.6% (9.3%) (good) | 70.6% (6.8%) (acceptable) | 54.7% (12.5%) (low) |
Domain 1 = scope and purpose; domain 2 = stakeholder involvement; domain 3 = rigor of development; domain 4 = clarity of presentation; domain 5 = applicability; domain 6 = editorial independence. Domain scores ≥80% = good; 60–79% = acceptable; 40–59% = low; <40% = very low. * = total score of domain >60%. BMD = Bone mineral density; ISCD = International Society for Clinical Densitometry; ACR = American College of Radiology; SPR = Society for Pediatric Radiology; SSR = Society of Skeletal Radiology; SD = standard deviation